# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive ...
Vivos' DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from...
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...